Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients: LIKELIHOOD OF LY2603618 TO INHIBIT CYP2D6 IN CANCER PATIENTS
Biopharmaceutics & Drug Disposition（2014）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined